This nonprofit is constructing the ecosystem to remedy epidermolysis bullosa

Epidermolysis bullosa, or EB, is a kind of illnesses that stops you in your tracks the second you perceive it. Pores and skin so fragile that the gentlest contact could cause blisters and open wounds. No remedy. And for many of its historical past, little or no severe drug improvement consideration.

That is the place right this moment’s visitor is available in. 

Martin Steiner is Managing Director of DEBRA Analysis, a non-profit group with a single-minded mission: to make EB curable. However DEBRA Analysis is not a lab. It does not run medical trials or make medication. What it does is one thing arguably tougher: it builds the ecosystem that makes drug improvement doable. Funding analysis, investing in biotech corporations, constructing shared infrastructure, and connecting the best folks on the proper time.

And the outcomes are beginning to present. They’ve a rising portfolio of investments, devoted medical trial infrastructure, and a seat on the desk in offers which are transferring the needle for sufferers who’ve waited lengthy sufficient.

·  01:46 Meet Martin Steiner

·  03:32 What’s DEBRA Analysis

·  04:55 What it means to reside with EB 

·  07:43 DEBRA Analysis’s position within the drug improvement ecosystem 

·  12:03 Why DEBRA Analysis invests in infrastructure 

·  20:26 Why DEBRA Analysis makes fairness investments in biotech 

·  24:50 The Replay and LEO Pharma deal: the way it got here collectively 

·  30:33 Obstacles to enabling collaboration in uncommon illness 

·  34:50 Gene remedy and read-through molecules as therapeutic approaches 

·  37:36 Is the DEBRA Analysis mannequin replicable for different uncommon illnesses 

Excited by being a sponsor of an episode of our podcast? Uncover how one can get entangled right here! 

Keep up to date by subscribing to our publication

To dive deeper into the subject: